Analyst Ratings For Akebia Therapeutics Inc (NASDAQ:AKBA)
Today, HC Wainwright lowered its price target on Akebia Therapeutics Inc (NASDAQ:AKBA) to $21.00 per share.
There are 5 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Akebia Therapeutics Inc (NASDAQ:AKBA) is Buy with a consensus target price of $14.6250 per share, a potential 240.91% upside.
Some recent analyst ratings include
- 5/2/2019-Akebia Therapeutics Inc (NASDAQ:AKBA) has coverage initiated with a Overweight ➝ Overweight rating and $12.00 price target
- 3/20/2019-Akebia Therapeutics Inc (NASDAQ:AKBA) has coverage initiated with a Neutral ➝ Neutral rating and $9.00 price target
- 12/4/2018-Akebia Therapeutics Inc (NASDAQ:AKBA) had its Buy rating reiterated by Mizuho with a $17.00 price target
- 9/7/2018-Akebia Therapeutics Inc (NASDAQ:AKBA) has coverage initiated with a Equal ➝ Weight rating
- 8/13/2018-Akebia Therapeutics Inc (NASDAQ:AKBA) has coverage initiated with a Buy rating and $18.00 price target
- On 2/15/2018 Duane Nash, Director, sold 1,000 with an average share price of $14.62 per share and the total transaction amounting to $14,620.00.
- On 10/2/2017 Duane Nash, Director, sold 1,188 with an average share price of $19.64 per share and the total transaction amounting to $23,332.32.
- On 10/2/2017 Michel Dahan, SVP, sold 1,398 with an average share price of $19.64 per share and the total transaction amounting to $27,456.72.
- On 9/28/2017 Michel Dahan, SVP, sold 5,000 with an average share price of $19.30 per share and the total transaction amounting to $96,500.00.
- On 8/15/2017 Michel Dahan, SVP, sold 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
- On 7/5/2017 Muneer A Satter, Director, bought 1,034,482 with an average share price of $14.50 per share and the total transaction amounting to $14,999,989.00.
- On 7/3/2017 Duane Nash, Director, sold 990 with an average share price of $14.27 per share and the total transaction amounting to $14,127.30.
About Akebia Therapeutics Inc (NASDAQ:AKBA)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Read More…
Recent Trading Activity for Akebia Therapeutics Inc (NASDAQ:AKBA)
Shares of Akebia Therapeutics Inc closed the previous trading session at 4.28 up +0.0050 0.12% with 4.2 shares trading hands.